Latest news with #IL-23R
Miami Herald
26-06-2025
- Business
- Miami Herald
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About ProtagonistProtagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Investor Relations ContactCorey Davis, Advisors+1 212 915 2577cdavis@ Media ContactVirginia Amann, Founder/CEOENTENTE Network of Companies+1 833 500 0061 ext 1virginiaamann@ SOURCE: Protagonist Therapeutics
Associated Press
26-06-2025
- Business
- Associated Press
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected] Media Contact Virginia Amann, Founder/CEO ENTENTE Network of Companies +1 833 500 0061 ext 1 [email protected] SOURCE: Protagonist Therapeutics press release
Associated Press
16-04-2025
- Business
- Associated Press
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company'), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the 'Grant Date'), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022. The new employee received options to purchase 20,000 shares of the Company's common stock on the Grant Date. The exercise price of the options is equal to $46.95, the closing price of the Company's common stock on the Nasdaq Stock Market on the Grant Date. The options will vest over a four-year period, with 25 percent of the options vesting on the first anniversary of the employee's start date and the remainder vesting in equal monthly installments over three years thereafter. The award was approved by the Compensation Committee of the Company's Board of Directors and was granted as a material inducement to the employee's entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4). About Protagonist Therapeutics Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected] Media Contact Virginia Amann, Founder/CEO ENTENTE Network of Companies +1 833 500 0061 ext 1 [email protected] SOURCE: Protagonist Therapeutics press release
